Following the concerns raised about the drug Avandia's heart risk, NEJM has published a report online on 5 June 2007 "Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis " with new data that come from the RECORD trial, sponsored by the drugmaker Glaxo, designed to assess the drug's effect on the heart.
The authors concluded that the interim findings from this study were inclusive, "Rosiglitazone was associated with an increased risk of heart failure", but "the data were insufficient to determine whether the drug was associated with an increase in the risk of myocardial infarction."
No comments:
Post a Comment